Table 3.
Clinicopathological characteristics and treatment regimens of the 3987 patients in the BCCA Cohort
| N | % | |
|---|---|---|
| Age (years) | ||
| < 40 | 294 | 7 |
| 40-49 | 843 | 21 |
| 50-65 | 1423 | 36 |
| > 65 | 1427 | 36 |
| Grade | ||
| 1 | 209 | 6 |
| 2 | 1562 | 41 |
| 3 | 2037 | 54 |
| N/A | 179 | |
| Menstrual status at referral | ||
| Pre-menopausal | 1178 | 30 |
| Post-menopausal | 2717 | 70 |
| N/A | 92 | |
| Nodal status | ||
| Negative | 2265 | 57 |
| Positive | 1714 | 43 |
| N/A | 8 | |
| Lymphovascular invasion | ||
| Negative | 2105 | 55 |
| Positive | 1709 | 45 |
| N/A | 173 | |
| Tumor size (cm) | ||
| ≤ 2 | 2077 | 52 |
| 2-5 | 1665 | 42 |
| >5 | 221 | 6 |
| N/A | 24 | |
| Initial Adjuvant Systemic Therapy | ||
| None | 1676 | 42 |
| Tamoxifen only | 1274 | 32 |
| Chemotherapy only (AC, FAC or CMF) | 725 | 18 |
| Tamoxifen and chemotherapy | 296 | 8 |
| Other | 16 |
Abbreviations: N/A, not available; AC, adriamycin and cyclophosphamide; FAC, 5-fluorouracil and AC; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil